NCT00309868 is a Phase 1/Phase 2 clinical trial of neseritide in Diastolic Heart Failure, sponsored by Massachusetts General Hospital.

Who is sponsoring NCT00309868?

NCT00309868 is sponsored by Massachusetts General Hospital.

What drugs are being tested in NCT00309868?

Interventions in NCT00309868: neseritide.

What condition does NCT00309868 study?

NCT00309868 studies Diastolic Heart Failure.

Is NCT00309868 still recruiting?

NCT00309868 is currently completed. Last updated 24 March 2014.

Last reviewed 2014-03-24 · How we verify

NCT00309868

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of the Acute Hemodynamic and Myocardial Effects of Nesiritide in Diastolic Heart Failure.

Completed Phase 1/Phase 2 Last updated 24 March 2014

What this trial tests

Phase 1/Phase 2 trial testing neseritide in Diastolic Heart Failure in 20 participants. Completed in 1 December 2003.

Timeline

1 December 2002

Primary endpoint
1 December 2003

1 December 2003

Quick facts

Lead sponsor	Massachusetts General Hospital
Phase	Phase 1/Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 December 2002
Primary completion	1 December 2003
Estimated completion	1 December 2003

Drugs / interventions tested

neseritide — full drug profile →

Conditions studied

Diastolic Heart Failure — all drugs for Diastolic Heart Failure →

Sponsor

Massachusetts General Hospital

Who can join

18 and older, any sex, with Diastolic Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

We hypothesize that nesiritide will have favorable effect in decreasing heart filling pressures and echocardiogram studies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diastolic Heart Failure

Currently open trials in the same condition.

NCT05408559 — Prevention of Age-associated Cardiac and Vascular Dysfunction Using Avmacol ES · Phase 1, PHASE2 · recruiting
NCT05064709 — Assessment of CCM in HF With Higher Ejection Fraction · NA · recruiting
NCT04160000 — Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure · Phase 4 · recruiting

Other Massachusetts General Hospital trials

Trials by the same sponsor.

NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00309868 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
Last refreshed: 24 March 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00309868.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing